Molecular Diagnostics for Transplant Companies

Natera Expanded its Prospera product line with Prospera with Quantification, the first commercially available cfDNA (cell-free DNA) test for non-invasive monitoring of kidney transplant rejection.

CareDx Received FDA approval for AlloMap Heart Care™, a next-generation gene expression test that improves the prediction of cardiac allograft vasculopathy (CAV) development after heart transplant.

Thermo Fisher Scientific Launched the TruSight Transplant One™ Kit, a comprehensive NGS (next-generation sequencing) assay enabling simultaneous analysis of HLA (human leukocyte antigen) typing, CMV (cytomegalovirus) and EBV (Epstein-Barr virus) detection, and chimerism testing in transplant patients.

• Thermo Fisher Scientific Inc. (US)


• BioMérieux SA (France)


• Cepheid (US)


• Altona Diagnostics GmbH (Germany)


• ELITechGroup (France)


• Hoffmann-La Roche Ltd. (Switzerland)


• Hologic Inc. (US)


• QIAGEN N.V. (Germany)


• Becton, Dickinson, and Company (US)


• Abbott Laboratories, Inc. (US)